share_log

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SEC announcement ·  Aug 6 04:57
Summary by Futu AI
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.